Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Okwundu, Charles I ^a   Okoromah, Christy A N ^b  

^a LAGOS UNIVERSITY TEACHING HOSPITAL   (Nigeria)

^b UNIVERSITY OF LAGOS   (Nigeria)

Author keywords

Adenine *analogs derivatives; Therapeutic use ; Anti HIV agents *therapeutic use ; Female; HIV infections *prevention control ; Humans; Phosphonic acids *therapeutic use ; Randomized controlled trials as topic; Risk

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE; TENOFOVIR DISOPROXIL;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COCHRANE LIBRARY; CREATININE BLOOD LEVEL; DATA EXTRACTION; DATA SYNTHESIS; DRUG EXPOSURE; EMBASE; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INFORMATION RETRIEVAL; MEDLINE; PHOSPHATE BLOOD LEVEL; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

EID: 70249118493     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007189.pub2     Document Type: Review

References (28)

1. Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K, et al.Tenofovir Disoproxil Fumarate for Preventionof HIV Infection in Women: A Phase 2, Double-Blind, randomized, Placebo-Controlled Trial. Plos CLINICAL TRIALS May 25, 2007. (Pubitemid 46851988)
2. Brooks JJ, Scott B, Estelle P, Linda A, Charles R, Craig H, et al.A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS March 2003;17(4):547-553.
3. VOICE study. Ongoing study 2008.
4. NCT00119106. Bangkok Tenofovir Study. clinicaltrials.gov/ct2/show/ NCT00119106 (accessed 20 June 2008).
5. NCT00131677. Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men. www.clinicaltrials.gov/ct2/show/NCT00131677 (accessed 10 June 2008).
6. NCT00448669 . Botswana TDF/FTC Oral HIV Prophylaxis Trial. www.clinicaltrials.gov/ct2/show/NCT00448669 (accessed 20 June 2008).
7. NCT00458393. Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men. www.clinicaltrials.gov/ct2/show/NCT00458393 accessed 20 June 2008.
8. NCT00557245. Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples (PartnersPrEP). www.clinicaltrials.gov/ct2/show/ NCT00557245 (accessed 20 June 2008).
9. FEMPrEP. Ongoing study 2008.
10. Australian federation of AIDS organization Inc. AFAO National forumon Prepexposure prophylaxis for HIV(PrEP): final report. A summary of the outcomes of the National forum held at Dockside, Cockle Bay on the 16th June, 2005.
11. AIDS News Release. Prevention in a tablet. www.ippf.org/NR/rdonlyres/ 80E7C1E6-2A56-4E18-ACEE-2ED784FD1FE5/0/Issue4-11-05.pdf (accessed 14 September 2007).
12. Alliance for Microbicide Development. HIV prophylaxis with reverse transcriptase inhibitors: microbicides and oral tablets. The Microbicide Quaterly 2006;4(4):1-7.
13. Center for HIV Identification, Prevention, and Treatment Services (CHIPTS). Anticipating the efficacy of HIV pre-exposure prophylaxis (PREP) and the needs of at-risk Californians. www.aidspartnershipca.org/assets/ PrepReport1104.pdf (accessed 13 September 2007).
14. AIDS Vaccine Advocacy Coalition (AVAC). Will a pill a day prevent HIV? anticipating the results of the tenofovir "PREP" trials. www.avac.org/AVAC-tenofovir-report-mar-2005.pdf (accessed 12 September 2007 ).
15. Bahuguna NJ. Putting women in charge. www.boloji.com/wfs5/wfs672.htm (accessed 14 September 2007).
16. Grant RM, Buchbinder S, Cates W Jr, Clarke E, Coates T, Cohen MS, et al.AIDS.Promote HIV chemoprophylaxis research, don't prevent it. Science 2005;309:2170-2171 (Pubitemid 41396056)
17. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al.A case-control study of HIV seroconversion in health care workers after percutaneous exposure. The New England Journal of Medicine 1997;337(21):1485- 1490 (Pubitemid 27495773)
18. Center for DIsease Control and Prevention. Q&A: CDC's clinical studies of pre-exposure prophylaxis for HIV prevention. www.cdc.gov/hiv/ resources/qa/pdf/prep.pdf (accessed 5 September 2007).
19. Global HIV Prevention Working Group. New approaches to HIV prevention. /www.paho.org/English/AD/FCH/AI/New%20Approaches%20to%20HIV%20Prevention. (accessed 09 September 2007).
20. Grant RM, Buchbinder S, Cates W Jr, Clarke E, Coates T, Cohen MS. Promote HIV chemoprophylaxis research, don't prevent it. Science 2005;309(5744):2170- 2171 (Pubitemid 41396056)
21. Guay L, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al.Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention ofmother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999;354:795-802. (Pubitemid 29415583)
22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
23. Highleyman L. Pre-exposure prophylaxis: a new focus for HIV prevention. AIDS 2006 16th International AIDS Conference; 2006 Aug 13-18; Toronto, Canada.
24. Julia M, Teresa H. An update on female-controlled methods for HIV prevention: female condom, microbicides and cervical barriers. The Southern African Journal of HIV Medicine 2006, (25):7-11.
25. Smith S. Pre-exposure chemoprophylaxis for HIV: it is time. Retrovirology 2004;1(1):16.
26. UNAIDS. Report on the global AIDS global AIDS epidemic. UNAIDS 2006.
27. J Volmink, NL Siegfried, L van der Merwe, P Brocklehurst. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD003510. DOI: 10.1002/14651858.CD003510.pub2.[Art. No.: CD003510. DOI: 10.1002/14651858. CD003510.pub2]
28. Youle M, Wainberg M. Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. Journal of the International Association of Physicians in AIDS Care 2003;2(3):102-105